Table 1.
Characteristics of included studies
| SN no | Study | Sample size | Study design | Country of study | Name of vaccine | Mean age | Gender (%) | Body mass index | Adverse reaction |
|---|---|---|---|---|---|---|---|---|---|
| 1 | [10] | 50 | Observational cohort | Austria | Pfizer | 67.6 |
M:34 F:16 |
NA | Local reaction, diarrhea, fatigue |
| 2 | [11] | 1256 | Prospective observational multicenter | Germany |
Pfizer modern |
67.6 |
M: 818 F: 438 |
27.5 | Local reaction, fever, joint pain, chills |
| 3 | [12] | 10 | Retrospective, observational | France | Pfizer | 71.2 |
M: 7 F: 3 |
NA | NA |
| 4 | [13] | 186 | Retrospective observational | USA |
Pfizer modern |
67.9 |
M:98 F:88 |
28.7 | NA |
| 5 | [14] | 154 | Prospective | Canada | Pfizer | 73 | M:101 F:53 | NA | Covid infection |
| 6 | [15] | 56 | Cohort | Israel | Pfizer | 74 | M:42 F:14 | 27.2 | NA |
| 7 | [16] | 78 | Cohort | France | Pfizer | 73.5 | M:46 F:32 | 26.8 | NA |
| 8 | Schrenzemeier et al (2021) | 36 | Cohort | Germany | Pfizer | 74 |
M:25 F:11 |
NA | NA |
Abbreviations: M, male; F, female; NA, not available.